Academic literature on the topic 'Cancers poumon et sein/ovaire'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancers poumon et sein/ovaire.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Cancers poumon et sein/ovaire":
Kachuri, L., P. De, LF Ellison, and R. Semenciw. "Tendances concernant l'incidence du cancer, la mortalité par cancer et la survie au cancer au Canada entre 1970 et 2007." Maladies chroniques et blessures au Canada 33, no. 2 (March 2013): 80–92. http://dx.doi.org/10.24095/hpcdp.33.2.03f.
Caygill, C. P. J. "Risques Héréditaires de Cancers du Sein et de 1’Ovaire (Hereditary Risks of Cancer of the Breast and Ovary)." European Journal of Cancer Prevention 7, no. 6 (December 1998): 483–84. http://dx.doi.org/10.1097/00008469-199812000-00015.
Wagner, Anna Dorothea, Khalil Zaman, Solange Peters, and Michael Montemurro. "Traitements [b]antiangiogéniques[/b] des cancers métastatiques du côlon et du rectum, du sein et du poumon : bénéfices et risques." Revue Médicale Suisse 6, no. 250 (2010): 1070–73. http://dx.doi.org/10.53738/revmed.2010.6.250.1070.
Kouassy, KY, O. Kimso, K. Traore, BA Oddo, A. Edoukou, DR Niang, KA Gaetan, SI Mounkeila, M. Toure, and I. Adoubi. "C103: Intérêt du Paclitaxel – Bévacizumab dans le cancer du sein triple négatif métastatique à Abidjan." African Journal of Oncology 2, no. 1 Supplement (March 1, 2022): S43. http://dx.doi.org/10.54266/ajo.2.1s.c103.jsle2071.
Giraud, P., J. Djadi-Prat, E. Morvan, M. Morelle, R. Remmonay, N. Pourel, C. Durdux, et al. "Intérêts dosimétriques et cliniques de la radiothérapie asservie à la respiration des cancers du poumon et du sein : résultats du Stic 2003." Cancer/Radiothérapie 16, no. 4 (July 2012): 272–81. http://dx.doi.org/10.1016/j.canrad.2012.03.005.
Wanigaratne, S., E. Holowaty, H. Jiang, TA Norwood, R. Pietrusiak, and R. Brown. "Estimation du risque de cancer lié à l'exposition au tritium dans le cadre des activités courantes de la centrale nucléaire de Pickering (Ontario)." Maladies chroniques et blessures au Canada 33, no. 4 (September 2013): 278–89. http://dx.doi.org/10.24095/hpcdp.33.4.06f.
Bousquet, P. J., P. Caillet, M. Coeuret-Pellicer, H. Goulard, Y. C. Kudjawu, C. Le Bihan, A. I. Lecuyer, and F. Séguret. "Recherche d’algorithmes d’identification des cancers dans les bases médico-administratives : premiers résultats des travaux du groupe REDSIAM Tumeurs sur les cancers du sein, du côlon-rectum et du poumon." Revue d'Épidémiologie et de Santé Publique 65 (October 2017): S236—S242. http://dx.doi.org/10.1016/j.respe.2017.04.057.
Latorzeff, I., C. Bourgier, B. Pinel, C. Hennequin, G. Jimenez, O. Chapet, and X. Zasadny. "Traitement de la maladie primitive (cancers du sein, du poumon non à petites cellules et de la prostate), par irradiation, au stade d’emblée métastatique." Cancer/Radiothérapie 23, no. 6-7 (October 2019): 486–95. http://dx.doi.org/10.1016/j.canrad.2019.08.004.
Cazaux, C. "R59 – Oral: La réplication non conventionnelle de l’ADN comme source de marqueurs pronostiques et de traitements ciblés dans les cancers du sein, du côlon et du poumon. ASCI structurante « les 3R comme signature péjorative de la maladie »." Bulletin du Cancer 97, no. 4 (October 2010): S38. http://dx.doi.org/10.1016/s0007-4551(15)30976-0.
Dissertations / Theses on the topic "Cancers poumon et sein/ovaire":
El, Kadiri Hanae. "Mise en évidence de l'activité antitumorale du taxol au moyen de tests in vitro sur cellules humaines : cancers bronchiques à petites cellules (lignée NCI-N 417), de l'ovaire et du sein." Université Joseph Fourier (Grenoble), 1988. http://www.theses.fr/1988GRE18002.
Ducrot, Lucas. "Réseaux bayésiens et analyse de survie pour l’estimation de courbes de pénétrance du cancer broncho-pulmonaire lié à des prédispositions génétiques." Electronic Thesis or Diss., Sorbonne université, 2024. http://www.theses.fr/2024SORUS055.
This thesis focuses on estimating penetrance curves of genetic diseases from pedigree data, with a particular interest in the genetic predisposition to bronchopulmonary cancer. In this context, it aims to provide clinical and epidemiological results, as well as methodological findings.Genetic counselling is offered to patients with severe family histories of genetic diseases. Geneticists must select from these patients who should be offered genetic testing, and assess the disease risks for these patients and their families. Advances in genetics are rapid, and the number of identified pathogenic variants for different diseases increases each year. This necessitates significant predictive and risk assessment tools, especially in the context of bronchopulmonary cancer. Indeed , the links between the latter and pathogenic variants (such that SFTPA1/SFTPA2 and the genes TP53 and EGFR) are known but still poorly described.Existing methods for assessing the risk of disease occurrence rely on penetrance curves, but their estimation faces challenges due to the small number of patients and the omnipresent selection bias in genetics-collected datasets. To overcome these obstacles, the thesis explores the use of familial data, employing a set of statistical tools including Bayesian networks, mixture models, survival analysis, as well as existing models, for which it attempts to weaken certain assumptions.Chapter 1 provides an overview of the medical context of the thesis, introducing the concepts of genetic diseases and genetic counseling. Chapter 2 serves as a methodological introduction, presenting and illustrating concepts such as survival analysis, Bayesian networks, sum-product algorithm, mixture models and EM algorithm, using examples. It also offers a state-of-the-art review of penetrance curve estimation for genetic diseases and highlights the selection bias in genetics. The chapter concludes with a summary of the addressed research questions.Then, the thesis revolves around four projects. The first two projects, corresponding to chapters 3 and 4, offer predominantly clinical and epidemiological results. The first project, described in Chapter 3, compares different methods for predicting pathogenic variants for breast/ovarian cancers (Manchester Score and family models like BOADICEA). The second project, addressed in Chapter 4, provides estimates of penetrance for interstitial lung disease and bronchopulmonary cancer for carriers of pathogenic variants SFTPA1 and SFTPA2.The last two projects, corresponding to chapters 5 and 6, are more methodological. Chapter 5 is dedicated to developing a new method for estimating the penetrance curve of a genetic disease from pedigree data when the disease presents sporadic cases. It is based on an incidence constraint of the disease in the general population and a parameterization of the relative hazard between carriers and non-carriers of pathogenic variants. Chapter 6 focuses on highlighting the bias introduced by selection in genetics and its consequences on the results of the method developed in Chapter 5. Known correction methods, such as Proband's Phenotype Exclusion Likelihood (PEL) and Genotype-Restricted Likelihood (GRL), combined with our method, are applied to simulated data
RICO, AGNES. "La stimulation ovarienne et les risques de cancers gynecologiques : a propos de deux observations du c.h.u. de nantes et d'une enquete aupres des centres francais de fecondation in vitro." Nantes, 1992. http://www.theses.fr/1992NANT054M.
Roger, Pascal. "Analyse par immunohistochimie de protéines oestrogeno-regulées dans les cancers du sein et les tumeurs épitheliales de l'ovaire." Montpellier 1, 1998. http://www.theses.fr/1998MON1T029.
Gad, Sophie. "Etude des prédispositions génétiques aux cancers du sein et de l'ovaire : recherche d'altérations de grande taille des gènes BRCA1 et BRCA2, recherche de facteurs génétiques modificateurs du risque de cancer de l'ovaire chez des femmes porteuses d'une mutation de BRCA1." Paris 5, 2002. http://www.theses.fr/2002PA05N028.
Tournier, Isabelle. "Mécanismes d'inactivation des gènes impliqués dans les deux formes majeures de prédisposition héréditaire aux cancers : la prédisposition aux cancers du sein et de l'ovaire et le cancer colorectal héréditaire non polyposique (HNPCC) ou syndrome de Lynch." Rouen, 2007. http://www.theses.fr/2007ROUE04NR.
Soussan, Michaël. "Developpement et applications cliniques de methodes de quantification en TEP pour le pronostic et le suivi therapeutique des cancers." Thesis, Paris 11, 2015. http://www.theses.fr/2015PA112135.
In the era of personalized medicine, genomics and targeted therapies, the availability of quantitative tools assisting the interpretation of medical images is essential. In Positron Emission Tomography (PET), beyond measurements of uptake intensity, it is possible to derive quantitative index characterizing the metabolic volume or the tumoral heterogeneity. The objective of this work was to investigate the value of new quantitative indices to enhance PET imaging, allowing for a more comprehensive analysis of the whole tumor. The first part of the work deals with methodological issues associated with the measurement of tumor heterogeneity using textural index. In particular, we identified the most robust and informative textural index for clinical applications. Two sets of patients have then been used to explore the contribution of metabolic volume and texture analysis in PET. In lung cancer patients, our results suggest that the measurement of tumor heterogeneity gives some information regarding the histological features of the tumor. A second set of results shows that metabolic volume is more relevant than conventional indices for evaluating the impact of neoadjuvant chemotherapy in locally advanced stages. A correlation between quantitative changes during treatment and post-treatment histology results was used to demonstrate the relevance of these indices. In breast cancer patients, our results suggest that tumors with aggressive immunohistological patterns, particularly triple-negative phenotype, have a more heterogeneous texture than other types. In summary, our results suggest that a more comprehensive quantitative characterization of the metabolic activity distribution in tumor using PET imaging improves the pre-therapeutic and prognostic evaluation of cancer
Vezain, Myriam. "Implication des altérations de l'épissage de l'ARN dans les cancers héréditaires et dans l'amyotrophie spinale infantile." Rouen, 2009. http://www.theses.fr/2009ROUES028.
This thesis deals with constitutional changes affecting RNA splicing in in two groups of genetics diseases: genetic predisposition to cancer and the neuromuscular disease spinal muscular atrophy (SMA). We developed minigene-based constructs functional assay to detect the effect on splicing of nucleotide variations of unknown significance. We applied this assay to the interpretation of mutations identified in the molecular diagnosis of genetic predisposition to colon cancer and to breast and ovarian cancer, and found that nearly 20% of the variation of unknown significance could be reclassified into splicing mutations. Some of these variants are located at a distance of consensus splice sites and can affect a splicing regulatory element. We developed a set of analytical tools to map these regulatory elements and to analyze them functionally. My work on SMA is in the context of clinical trials based on the correction of the defective splicing of SMN2 transcripts. We developed and validated a sensitive and robust method to determine mRNA expression from the SMN2 gene. The last part of my work describes the study of a patient with only two copies of the SMN2 gene and an unexpectedly moderate clinical phenotype (type III SMA). We showed that a rare mutation on both copies of the SMN2 gene of this patient enhanced inclusion of exon 7 into the mRNA of SMN2. The biochemical investigation of this variant has highlighted previously unrecognized aspects of the regulation of splicing of exon 7 of SMN genes
Victoor, Camille. "Rôle oncogénique de nétrine-1 dans la plasticité cellulaire : mécanismes d’action et potentiel thérapeutique. Exemples des cancers mammaires,ovariens et des synovialosarcomes." Electronic Thesis or Diss., Lyon 1, 2023. http://www.theses.fr/2023LYO10148.
Belonging to the laminin family, netrin-1 is a small secreted molecule with a wide range of functions now described. As a developmental protein, netrin-1 is minimally or not expressed in healthy adult tissues. However, in pathological contexts such as cancer, a re- expression of the protein is observed, involving the activation of associated signaling pathways and leading to various processes such as cell survival, angiogenesis, and inflammation. The research presented in this manuscript has highlighted the role of netrin-1 in cellular plasticity, a crucial mechanism in tumor development and a significant therapeutic challenge due to its properties of self-renewal, cell migration, and therapy resistance. Through the study of examples in breast and ovarian cancer stem cells, as well as synovial sarcomas, this manuscript describes the critical role of netrin-1 in cellular plasticity and how a monoclonal therapeutic antibody targeting this protein represents a promising therapeutic strategy
Billaud, Amandine. "Analyse moléculaire, enjeux et limites des thérapies ciblées en oncologie : extension des sensibilités aux anti-PARP dans les cancers ovariens par caractérisation de variants non annotés et nouveaux mécanismes de résistance dans les cancers bronchiques. Caractérisation moléculaire de l’EGFR dans les cancers bronchiques non à petites cellules : étude prospective comparative des technologies NGS et automate Idylla Somatic mRNA analysis of BRCA1 splice variants provides a direct theranostic impact on PARP inhibitors." Thesis, Angers, 2020. http://www.theses.fr/2020ANGE0003.
Despite significant clinical benefit from the consideration of molecular context, targeted therapies are still challenging. First part of this work focused on tyrosine kinase inhibitors targeting EGFR in non small cell lung cancers. Thus, improvement of biomarkers detection methods was completed by in vitro characterization of an unreported mechanism of acquired resistance. Briefly, pulmonary cells were exposed to a mutagen agent and a selection pressure was applied with EGFR inhibitors allowing the detection of TBK1 signature. Finally, synergic effect of that co-inhibition was highlighted. Now essentials in gynaecological cancers management, PARP inhibitors represent the second part of that work. Those targeted therapies are based on synthetic lethality. Consequently, BRCA1/2 pathogenic mutations are required for their administration, illustrating the issue of variants of uncertain significance. Toward their functional characterization necessity, a transcriptional analysis of splicing variant was first conducted on mRNA extracted from FFPE samples. Then, to evaluate functional signification of all types of variants, genomic edition was developed. Editing efficiencies of the unknown variant and a silent control one were compared in a haploid model where those genes are essentials. Functional signification of BRCA1/2 variants, and thereby mutations from all essential tumor suppressor genes in our model, can be evaluated in three weeks which is compatible with clinical management